Table 1. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE, ≤grade 3).

	Grade
	1	2	3
Conjunctivitis/ocular surface disease	Asymptomatic or minimally symptomatic; however, not interfering with the function	Symptomatic, significant discharge; interfering with function but not ADL; topical antibiotics or other topical intervention indicated	Symptomatic and interfering with ADL, operative intervention indicated
Keratitis (corneal inflammation/corneal ulceration)	Abnormal ophthalmologic changes only, intervention not indicated	Symptomatic and interfering with function, but not ADL	Symptomatic and interfering with ADL, operative intervention indicated
Anorexia	Coaxing or dietary change required to maintain appetite	Oral intake altered (≤3 days) without significant weight loss; oral nutritional supplements/appetite stimulants may be indicated	Of >3 days duration; associated with significant weight loss (≥10%) or malnutrition; IV fluids, tube feeding, or force-feeding indicated
Diarrhea	Increase of up to two stools per day over baseline; no increase in frequency; however, consistency decreased over baseline	Increase of 3–6 stools per day over baseline; medications indicated; parenteral (IV or SC) fluids indicated ≤48 hr; not interfering with ADL	Increase of >6 stools per day over baseline; incontinence >48 hr; IV fluids >48 hr; hospitalization; interfering with ADL
Hyperpigmentation (Dermatologic)	Slight or localized	Marked or generalized
Bilirubin	>ULN to 1.5× ULN	>1.5 −3.0 × ULN	>3.0–10 × ULN

ADL: activities of daily living (eating, sleeping, defecating, and urinating), ULN: upper limit of normal.